Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 2Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Endocrine 2NET 1

Conditions

Neuroendocrine Tumors 4Carcinoma, Neuroendocrine 2Serotonin Syndrome 1Paraganglioma 1Neoplasm Metastasis 1Carcinoid Tumor 1Carcinoid Heart Disease 1

Interventions

Cisplatin 3surufatinib 2sintilimab 2lutetium Lu 177 dotatate 2N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 2Fluorodeoxyglucose F18 2Everolimus 2toripalimab 1copper dotatate CU-64 1Radiopharmaceuticals 1PE regimen 1Nivolumab 1Interferon-alpha 1IFL protocol 1Gemcitabine 1Fluorouracil 1Etoposide 1EC regimen 1Copper 1Carboplatin 1Capecitabine 1Bevacizumab 164Cu-DOTATATE 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × Carcinoma, Neuroendocrine × lutetium Lu 177 dotatate × Clear all
NCT02236910 2024-10-15

Lu-DOTA-TATE

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Phase 2 Unknown
66 enrolled
Endocrine

Carcinoma, Neuroendocrine

NCT04525638 2022-08-02

A Clinical Study to Assess the Combination of Two Drugs (177Lu-DOTATATE and Nivolumab) in Neuroendocrine Tumours

Fundación de investigación HM

Phase 2 Unknown
30 enrolled
EndocrineNET

Carcinoma, Neuroendocrine, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡